AI Is Coming for Your Revenue Cycle. Here's What That Actually Means.
EY just published a piece on AI-driven RCM. It's worth reading — not because it breaks new ground, but because when the Big Four starts writing about denial prediction and NLP-assisted documentation, the adoption curve has shifted. Here's what they got right, and what the piece glosses over.
What EY Got Right
The framing is accurate: RCM has historically been treated as a back-office cost center, and that's exactly why it's been underfunded and under-optimized for decades. The insight that AI can reposition the revenue cycle as a value creator — not just a cost — is the right mental model.
The specific use cases they highlight are also legitimate:
- Predictive denial prevention — identifying which claims will deny before submission is genuinely valuable. First-pass resolution rate is the metric that matters, and AI models trained on payer behavior patterns can move that number.
- Eligibility resolution before the visit — not after denial. This is where most health systems leak money quietly, and automation has a clear ROI.
- NLP-supported documentation — ensuring clinical notes support medical necessity prior to coding is one of the highest-leverage interventions available right now.
- Auto-generated appeals — aligned to payer-specific logic, not generic templates. This is where the real vendor differentiation is happening.
The Stat That Matters
54% of providers say claim errors are increasing. 59% plan to invest in claims processing or denial reduction technology in the next six months. That's not a future trend — that's an active buying cycle.
What the Piece Glosses Over
EY frames this as a strategic transformation initiative, which creates the impression that AI-driven RCM requires a large-scale consulting engagement to unlock. That's their business model talking.
The reality for most provider organizations — especially independent practices and mid-sized groups — is that the tools exist today, at reasonable cost, and the ROI is calculable without a six-month roadmap. The question isn't whether to adopt AI in the revenue cycle. It's which specific workflows to target first and which vendors actually deliver.
The piece also avoids a real tension: payers are deploying AI too. Their denial engines are getting faster and more sophisticated. Providers who don't respond with AI-capable submission and appeals workflows are going to face a widening gap in first-pass rates. This isn't a future risk — it's happening now.
The Practical Takeaway
If you're an RCM leader, the question to ask isn't "should we invest in AI?" It's "where in our denial workflow is AI-preventable revenue leaking today?"
Start with your top five denial reason codes by dollar volume. If any of them are documentation-related or eligibility-related, there's an AI intervention with measurable ROI waiting. You don't need a transformation program — you need a targeted deployment against a specific problem.
The organizations that will win the next three years of revenue cycle aren't the ones that complete the biggest transformation. They're the ones that deploy targeted automation against specific leakage points, measure it, and iterate.
Stay ahead of RCM technology shifts
RevCycleAI delivers daily intelligence on the vendors, policy changes, and technology moves reshaping healthcare revenue cycle. Free to subscribe.
Subscribe Free →